Zydus Cadila has received tentative approval from the USFDA to market Linagliptin Tablets, 5 mg (US RLD: Tradjenta® Tablets). Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes mellitus.
The drug will be manufactured at the group’s formulation manufacturing facility at the SEZ, Ahmedabad.
The group now has 310 approvals and has so far filed over 390 ANDAs since the commencement of the filing process in FY 2003-04.
Shares of CADILA HEALTHCARE LTD. was last trading in BSE at Rs.417.95 as compared to the previous close of Rs. 423.2. The total number of shares traded during the day was 67181 in over 1387 trades.
The stock hit an intraday high of Rs. 427.5 and intraday low of 417. The net turnover during the day was Rs. 28348589.
#Zydus #Cadila #receives #tentative #approval #USFDA #Linagliptin #Tablets